HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
|
|
- Amice Walters
- 6 years ago
- Views:
Transcription
1 Generic Brand HICL HCN Exception/Other PALIVIZUMAB SYNAGIS Synagis may be covered during the RSV season from October 15, 2017 and March 31, If the PA is received prior to October 15, 2017, proactive approvals should include a start date of 10/15/2017. GUIDELINES FOR USE 1. Does the patient have hemodynamically significant cyanotic or acyanotic congenital heart disease (including those with moderate to severe pulmonary hypertension and those who are receiving medication to control congestive heart failure)? If yes, continue to #3. If no, continue to #2. 2. Does the patient have chronic lung disease (CLD) and has received medical therapy (supplemental oxygen, bronchodilator, diuretic, or chronic corticosteroid therapy) for CLD within 6 months before the start of RSV season (since 4/15/2017)? If yes, continue to #3. If no, continue to #4. 3. Is the patient less than 24 months of age? medication is only covered for patients less than 24 months of age with an increased risk of severe Respiratory Syncytial Virus (RSV) infection due to either chronic lung disease or congenital heart disease. The patient is over 24 months of age and therefore the request was not approved. 4. Does the patient have significant congenital abnormalities of the airways or a neuromuscular disease that compromises the handling of respiratory tract secretions? If yes, continue to #5. If no, continue to #6. Page 1
2 5. Is the patient less than 12 months of age at the start of RSV season? medication is only covered for patients with significant congenital abnormalities of the airways or a neuromuscular disease that compromises the handling of respiratory tract secretions who are less than 12 months of age at the start of RSV season. The patient is or will be 12 months of age or older at the start of RSV season and therefore the request was not approve. 6. Was the patient born prior to 35 weeks gestational age? If yes, continue to #7. medication is only covered for patients with an increased risk of severe Respiratory Syncytial Virus (RSV) infection based on certain medical conditions including chronic lung disease, congenital heart disease, congenital abnormalities of the airway, neuromuscular disease, or premature birth with or without certain environmental factors. The physician did not indicate that the patient is at an increased risk of severe RSV infection and therefore the request was not approved. 7. Was the patient born at or prior to '28 weeks, 6 days' gestational age and is less than 12 months of age at the start of RSV season? If no, continue to #8. 8. Was the patient born at '29 weeks, 0 days' through '31 weeks, 6 days' gestational age and is less than 6 months of age at the start of RSV season? If no, continue to #9. Page 2
3 9. Was the patient born at '32 weeks, 0 days' through '34 weeks, 6 days' gestational age and is less than 3 months old at the start of RSV season? If yes, continue to #10. medication is only covered for infants with an increased risk of severe Respiratory Syncytial Virus (RSV) infection based on their gestational age at birth and chronological age at the start of RSV season. Synagis is covered for patients who are born at less than 29 weeks gestational age and are less than 12 months of age at the start of RSV season, patients who are born at 29 weeks through 31 weeks, 6 days gestational age and are less than 6 months of age at the start of RSV season, and patients who are born at 32 weeks through 34 weeks, 6 days gestational age and are less than 3 months old at the start of RSV season. The patient's gestational age at birth and chronological age do not meet these requirements and therefore the request was not approved. 10. Does the infant attend child care/daycare? If yes, continue to #13. If no, continue to # Does the infant have a sibling younger than 5 years of age living permanently in the home (multiple births younger than 1 year of age do not qualify)? If yes, continue to #13. medication is only covered for a patients who was born at 32 weeks through 34 weeks, 6 days gestational age and is less than 3 months old at the start of RSV season if the patient is either attending child care/daycare or has a sibling younger than 5 years of age living permanently in the home (multiple births younger than 1 year of age do not qualify). The patient does not meet this requirement and therefore the request was not approved. Page 3
4 12. Approve up to 5 doses by HICL AND up to 5 fills. Please enter a minimum days supply of 28 and maximum # of vials per fill of 2 for patients < 20 kg (44 lbs). For patients 20 kg, please enter a minimum days supply of 28 and maximum # of vials per fill of 3. The number of approved doses is dependent on the month when the child starts prophylaxis: Child born before the start of RSV season: starting on October 15, 2017, approve up to 5 doses through 3/31/2018; fill count = 5. Infant born in November: approve up to 5 doses through 3/31/2018; fill count = 5. Infant born in December: approve up to 4 doses through 3/31/2018; fill count = 4. Infant born in January: approve up to 3 doses through 3/31/2018; fill count = 3. Infant born in February: approve up to 2 doses through 3/31/2018; fill count = 2. Infant born in March: approve 1 dose through 3/31/2018; fill count = 1. Additional doses are dependent on RSV virology persisting after March. Please use status code #057 and the approval text provided. PAC NOTE: Please forward a copy of the approval letter to CVS Specialty (Fax: APPROVAL TEXT: Synagis has been approved for your condition for [# of approved doses] doses to be ordered between October 15, 2017 and March 31, Approve up to 3 doses by HICL AND up to 3 fills. Please enter a minimum days supply of 28 and maximum # of vials per fill of 2 for patients < 20 kg (44 lbs). For patients 20 kg, please enter a minimum days supply of 28 and maximum # of vials per fill of 3. The number of approved doses is dependent on the month when the child starts prophylaxis: Child born before the start of RSV season: starting on October 15, 2017, approve up to 3 doses through 3/31/2018; fill count = 3. Infant born in November: approve up to 3 doses through 3/31/2018; fill count = 3. Infant born in December: approve up to 3 doses through 3/31/2018; fill count = 3. Infant born in January: approve up to 3 doses through 3/31/2018; fill count = 3. Infant born in February: approve up to 2 doses through 3/31/2018; fill count = 2. Infant born in March: approve 1 dose through 3/31/2018; fill count = 1. Additional doses are dependent on RSV virology persisting after March. Please use status code #057 and the approval text provided. PAC NOTE: Please forward a copy of the approval letter to CVS Specialty (Fax: APPROVAL TEXT: Synagis has been approved for your condition for [# of approved doses] doses to be ordered between October 15, 2017 and March 31, Page 4
5 RATIONALE To ensure the optimal use of palivizumab in high-risk patients for the prophylaxis of RSV. FDA APPROVED INDICATIONS For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth ( 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). REFERENCES MedImmune, Inc. Synagis package insert. Gaithersburg, MD. April American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112(6): American Academy of Pediatrics. Policy statement modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: American Academy of Pediatrics, Subcommittee on Diagnosis and Management of Bronchiolitis. Pediatrics 2006; 118; American Academy of Pediatrics, Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infections. Pediatrics 2014:134: Reducing RSV hospitalizations. AAP modifies recommendations for use of palivizumab in high-risk infants, young children. AAP News 2009; 30:1. Thomas Healthcare. Palivizumab. DRUGDEX System [database online]. Greenwood Village, CO. [Accessed: August ]. Created: 08/21/12 Effective: 09/18/17 Client Approval: 09/12/17 P&T Approval: 09/11/17 Page 5
Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationVIRGINIA MEDICAID s SYNAGIS SERVICE AUTHORIZATION Season: October 1 through March 31
VIRGINIA MEDICAID s SYNAGIS SERVICE AUTHORIZATION Season: October 1 through March 31 COMMONWEALTH of VIRGINIA Department of Medical Assistance Services Patient s Name: Patient s Medicaid ID#: (12 digits)
More informationPalivizumab (Synagis ) Criteria for the Respiratory Syncytial Virus (RSV) Season for Fee-For-Service Legacy Medicaid Recipients
Palivizumab (Synagis ) Criteria for the 2017-2018 Respiratory Syncytial Virus (RSV) Season for Fee-For-Service Legacy Medicaid Recipients Palivizumab is indicated for the prevention of serious lower respiratory
More informationRE: Season for Respiratory Syncytial Virus Prophylaxis for High-Risk Infants
Ministr y o f He alth and Lon g-term Ca re Ontario Public Drug Programs Division Drug Programs Delivery Branch 3 rd Floor, 5700 Yonge Street Toronto ON M2M 4K5 Telephone: (416) 327-8109 Toll Free: 1-866-811-9893
More informationLearn more about why severe RSV disease APPROVED USE
Learn more about why severe RSV disease can turn a welcome home into a welcome back to the hospital APPROVED USE SYNAGIS (palivizumab) is a prescription medication that is used to help prevent a serious
More informationAMERICAN ACADEMY OF PEDIATRICS. Committee on Infectious Diseases
Early Release: 8/24/09 AMERICAN ACADEMY OF PEDIATRICS Committee on Infectious Diseases POLICY STATEMENT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health
More informationSYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
US-10672 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab)
More informationUnderstanding RSV Testing
TECHNICAL BULLETIN Vol. 1 No. 1, September 2004 Understanding RSV Testing 1 RSV Facts 2 3 Synagis and Its Effects On RSV Testing Choosing a Rapid RSV Test 4 5 6 BD Directigen RSV Technology: Two antibodies
More informationHospitalization rates of premature and early term infants with RSV bronchiolitis. Leon Joseph MB ChB Pediatric Pumonology Shaare Zedek Medical Center
Hospitalization rates of premature and early term infants with RSV bronchiolitis Leon Joseph MB ChB Pediatric Pumonology Shaare Zedek Medical Center Conflicts of Interest Supported in part by an unrestricted
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationRisk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection
144 The Open Microbiology Journal, 2011, 5, (Suppl 2-M4) 144-154 Open Access Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Constanze Sommer 1, Bernhard Resch 1,
More informationReview Antibodies for prevention and treatment of respiratory syncytial virus infections in children
Antiviral Therapy 2012; 17:201 211 (doi: 10.3851/IMP2061) Review Antibodies for prevention and treatment of respiratory syncytial virus infections in children Bessey Geevarghese 1, Eric AF Simões 1,2,3
More informationGregory A. Prince, 1 Amy Mathews, 1 Spencer J. Curtis, 1 and David D. Porter 2
1326 Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systemically Administered Monoclonal Antibody (Palivizumab) and Glucocorticosteroid Gregory A. Prince,
More informationThe Prevention of Respiratory Syncytial Virus Infection in Children: Focus on Palivizumab
REVIEW The Prevention of Respiratory Syncytial Virus Infection in Children: Focus on Palivizumab Michael E. Speer and Amy B. Good Baylor College of Medicine, Houston, TX, U.S.A. Abstract: Recurrent upper
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationSovaldi Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Sovaldi Pegasys
More informationRespiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age
ORIGINAL RESEARCH Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age Brandi Newby and Todd Sorokan ABSTRACT Background: Immunoprophylaxis
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationAbout Clinical Trials
About Clinical Trials A guide for people with CF and their families INSIDE Who Can Participate in a Clinical Trial? Clinical Research Basics Who Is Involved in Clinical Research? Informed Consent Your
More informationRecommendations on eligibility to PRIME scheme
1 June 2016 EMA/345382/2016 Press office Adopted at the CHMP meeting of 23-26 May 2016 During its May 2016 meeting, the CHMP reviewed 18 recommendations for eligibility to PRIME: 4 were granted and 14
More informationVolume 27, Number 1 January 2013
Volume 27, Number 1 January 2013 FMULARY UPDATE The Pharmacy and Therapeutics Committee met November 20, 2012. 4 products were added in the Formulary and no drugs were deleted or designated nonformulary
More informationTHE BURDEN OF DISEASE ASSOCIATED WITH RESPIRATORY SYNCYTIAL VIRUS IN AUSTRALIA
National Centre for Social and Economic Modelling University of Canberra THE BURDEN OF DISEASE ASSOCIATED WITH RESPIRATORY SYNCYTIAL VIRUS IN AUSTRALIA Geetha Ranmuthugala Laurie Brown Brett A. Lidbury
More informationFDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.
Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of an Individual Patient with an Investigational Drug or a REMS-restricted, Approved Drug Guidelines:
More informationAdvanced Therapies for the Immune Compromised
Advanced Therapies for the Immune Compromised CORPORATE OVERVIEW SEPTEMBER 2015 1 WWW.ADMABIOLOGICS.COM FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements", pursuant to the
More informationTherapeutic Dosing of Unfractionated Heparin - Neonatal/Pediatric - Inpatient Clinical Practice Guideline
Therapeutic Dosing of Unfractionated Heparin - Neonatal/Pediatric - Inpatient Clinical Practice Guideline Note: Active Table of Contents Click to follow link Table of Contents EXECUTIVE SUMMARY... 3 SCOPE...
More informationThe Clinical Investigation Policy and Procedure Manual
The Clinical Investigation Policy and Procedure Manual Innovation Versus Research: Guidelines, Concepts and Procedures for Differentiation Guidelines The President s Commission on the Protection of Human
More informationVariable Resistance to Palivizumab in Cotton Rats by Respiratory Syncytial Virus Mutants
MAJOR ARTICLE Variable Resistance to Palivizumab in Cotton Rats by Respiratory Syncytial Virus Mutants Xiaodong Zhao, 1 Fu-Ping Chen, 1 A. George Megaw, 1 and Wayne M. Sullender 1,2 Departments of 1 Pediatrics
More informationPIP s Pup s and Problems
PIP s Pup s and Problems Graham Bailey, Senior Scientific Director and Fellow Reproductive and Juvenile Toxicology Drug Safety Sciences Janssen Pharmaceutica N.V Pediatric Medicine Until ~10 years ago,
More informationOff Label or On Target? The Ethics of Investigational and Compassionate Uses
Off Label or On Target? The Ethics of Investigational and Compassionate Uses G. Kevin Donovan, MD, MA Director, Pellegrino Center for Clinical Bioethics Professor of Pediatrics Georgetown University School
More informationGuidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical
Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved
More informationCorporate Medical Policy Genetic Testing for Fanconi Anemia
Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2017 3/2018 12/2017 Description
More informationQUICK REFERENCE INSTRUCTIONS For use with Sofia and Sofia 2. Rx only
QUICK REFERENCE INSTRUCTIONS For use with Sofia and Sofia 2. Rx only Test Procedure Study the Package Insert and User Manual thoroughly before using Quick Reference Instructions. This is not a complete
More informationPEDIATRIC CARDIOLOGY TODAY
P E D I A T R I C C A R D I O L O G Y T O D A Y R E L I A B L E I N F O R M A T I O N I N P E D I A T R I C C A R D I O L O G Y VOLUME 2, ISSUE 7 WWW.PEDIATRICCARDIOLOGYTODAY.COM JULY 2004 INSIDE THIS
More informationEFE EWORUKE, PH.D. H: C:
Eworuke E Page 1 Professional Summary EFE EWORUKE, PH.D H: 817-656-7320 C: 3522144202 email: efeodia@yahoo.com Epidemiologist, SAS Certified Programmer with experience in government and academic institutions,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.44 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationReproductive Management of Commercial Beef Cows. Ted G. Dyer, Extension Animal Scientist
Reproductive Management of Commercial Beef Cows Ted G. Dyer, Extension Animal Scientist Reproductive efficiency has long been recognized as the most important aspect of commercial beef production. If only
More informationPPTA Regulatory Workshop June 13, 2016
PPTA Regulatory Workshop June 13, 2016 DOROTY SCOTT Dr. Dorothy Scott is the Branch Chief for the Laboratory of Plasma Derivatives, in the Office of Blood Research and Review, CBER. Her group is responsible
More informationThe Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective
The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics
More informationSummary of the Family and Medical Leave Act of 1993
Summary of the Family and Medical Leave Act of 1993 The Family and Medical Leave Act of 1993 (FMLA) was enacted on August, 1993. It requires public agencies to provide up to twelve weeks (60 work days;
More informationD4.4 Midterm recruitment report Clinical study 4 - COPD cohort
D4.4 Midterm recruitment report Clinical study 4 - COPD cohort 116019 - RESCEU REspiratory Syncytial virus Consortium in EUrope WP4 Prospective data collection Lead contributor Other contributors Louis
More informationFAMILY AND MEDICAL LEAVE ACT OF 1993
Division of Administrative Services HUMAN RESOURCES FAMILY AND MEDICAL LEAVE ACT OF 1993 Employee Packet Division of Administrative Services HUMAN RESOURCES North End Center 300 Turner St. NW Suite 2300
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationACA & PBJ COMPLIANCE GUIDES (A.K.A. HOW TO STAY PENALTY FREE) V4 (0601F)
ACA & PBJ COMPLIANCE GUIDES (A.K.A. HOW TO STAY PENALTY FREE) V4 (0601F) LEGAL DISCLAIMER ACA and PBJ Compliance, Publications and Content The ACA and PBJ Compliance Guide is intended to be used as a handbook
More informationMEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication
MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication Guide each time you get more ribavirin tablets. There may
More informationVAE Questions and Case Studies
VAE Questions and Case Studies Cindy Gross, MT, SM (ASCP), CIC IP Consultant April 30, 2014 National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Review
More informationRSV vaccine development for Low and Middle Income Countries: Challenges and Progress
Global Vaccine and Immunization Research Forum RSV vaccine development for Low and Middle Income Countries: Challenges and Progress Claudio F. Lanata, MD, MPH Senior Researcher, Instituto de Investigación
More informationClinical Trials in Taiwan Regulatory Achievement and Current Status
Clinical Trials in Taiwan Regulatory Achievement and Current Status Hui-Po Wang, Ph.D. Director General, Bureau of Pharmaceutical Affairs, Department of Health, Taiwan Sue, Shu-Yi Chen, Pharmacist Division
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationFAMILY AND MEDICAL LEAVE ACT (FMLA) FREQUENTLY ASKED QUESTIONS (FAQ)
FAMILY AND MEDICAL LEAVE ACT (FMLA) FREQUENTLY ASKED QUESTIONS (FAQ) References: TSA MD 1100.63-1, Absence and Leave, and the associated Handbooks The MD and Handbook are the official TSA policy documents.
More informationActing Deputy Commissioner for Operations, U.S. Food and Drug Administration
Available on FDA website at: http://www.fda.gov/newsevents/testimony/ucm113266.htm Pediatric Clinical Trials for Anti-depressant Drug Products Statement of Janet Woodcock, M.D. Acting Deputy Commissioner
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B006 Page 1 of 5 and Therapeutics Quality PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationINSTRUCTIONS: HOW TO COMPLETE THE AVASTIN PATIENT
INSTRUCTIONS: HOW TO COMPLETE THE AVASTIN PATIENT ASSISTANCE PROGRAM ENROLLMENT FORM Phone: (888) 249-4918 Fax: (888) 249-4919 www.avastinaccesssolutions.com Enrollment Requirements Complete the Enrollment
More informationThe KIDSNET Concept:
Planning for Change: Technology Assessment of Rhode Island s National Immunization Conference Chicago, IL March 17, 2003 Noam H. Arzt, Ph.D. President, HLN Consulting, LLC Amy Zimmerman, MPH Chief Children
More informationAvailability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for
This document is scheduled to be published in the Federal Register on 06/04/2013 and available online at http://federalregister.gov/a/2013-13083, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationImmunoglobulin Database Report 2015/16
Immunoglobulin Database Report 2015/16 1 Database Overview Rob Hollingsworth CHAPTER 1 Introduction I would firstly like to thank all Trusts and their staff that continue to support and provide data to
More informationWarmth and Wellbeing Scheme
Warmth and Wellbeing Scheme www.seai.ie 1 Warmth and Wellbeing Scheme The Warmth and Wellbeing Scheme aims to make homes warmer and healthier to live in. It does this by providing extensive energy efficiency
More informationRegulatory Pathways for Rare Diseases
Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case
More informationSmall Interfering RNA s Molecular biology and use in therapy
Small Interfering RNA s Molecular biology and use in therapy Dr Stuart Hamilton - NHMRC Early Career Fellow Serology and Virology Division, SEALS Microbiology, Prince of Wales Hospital; School of Women
More informationREQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:
Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE
More informationINTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationNASDAQ: ABEO
NASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933,
More informationFrequently Asked Questions San Francisco Family Friendly Workplace Ordinance San Francisco Administrative Code 12Z
Overview The Family Friendly Workplace Ordinance (FFWO) is a local City and County of San Francisco ordinance that gives employees who work for employers with 20 or more employees and have worked for 6
More informationYour Prescription Drug [ or 20%] Plan with Refill By Mail
Refill By Mail The Home Delivery Pharmacy sends drugs you take on a regular basis right to your door. And you get a larger supply of medicine for less money. 1 Your Prescription Drug [15-40-75 or 20%]
More informationTechnology Trends and Impacts on CDI Programs. Tim Minnich, Solution Sales Executive, Mobile:
Technology Trends and Impacts on CDI Programs Tim Minnich, Solution Sales Executive, Tim.minnich@optum.com Mobile: 610-587-7366 Computer Assisted Coding & NLP The use of computer software that automatically
More informationTestimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory
More informationOfficial Letter from DOH
Issued Date 2008/08/19 Issued by DOH Ref. No 0970329838 RE To announce the Guidance for Good Pharmacovigilance Practice Attachment Guidance for Good Pharmacovigilance Practice Official Letter from DOH
More informationUpdate on the IVDR. Sue Spencer
Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application
More informationLeveraging the Electronic Health Record for Population Decision Support and Quality Measurement. Jonathan S. Einbinder, MD, MPH
Leveraging the Electronic Health Record for Population Decision Support and Quality Measurement Jonathan S. Einbinder, MD, MPH Eighth National Quality Colloquium August 18, 2009 1 Objective Develop awareness
More informationNational Drug Codes Requirement for UnitedHealthcare Community Plan. Calculating the Appropriate Number of National Drug Code (NDC) Units
National Drug Codes Requirement for UnitedHealthcare Community Plan Calculating the Appropriate Number of National Drug Code (NDC) Units National Drug Code Requirement Effective for claims with a date
More informationAmerican Thoracic Society Foundation. Research
American Thoracic Society Foundation Research Science knows no country because knowledge belongs to humanity and is the torch which illuminates the world. Louis Pasteur Founded in 1905 as the American
More informationClinical Policy: Eculizumab (Soliris) Reference Number: ERX.SPMN.225
Clinical Policy: (Soliris) Reference Number: ERX.SPMN.225 Effective Date: 01/17 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationLeading Canadian Pediatric Hospital Continues to Drive Dose Down for Sick Children
Leading Canadian Pediatric Hospital Continues to Drive Dose Down for Sick Children At Canada s premier pediatric hospital also recognized as one of the world s foremost pediatric healthcare institutions
More informationAssociation between Surfactant Protein A Gene Locus and Severe Respiratory Syncytial Virus Infection in Infants
283 Association between Surfactant Protein A Gene Locus and Severe Respiratory Syncytial Virus Infection in Infants Johan Löfgren, 1,2 Mika Rämet, 4 Marjo Renko, 1 Riitta Marttila, 3 and Mikko Hallman
More informationIgG Antibodies TO Rubella Virus ELISA Kit Protocol
IgG Antibodies TO Rubella Virus ELISA Kit Protocol (Cat. No.:EK-310-81) 330 Beach Road, Burlingame CA Tel: 650-558-8898 Fax: 650-558-1686 E-Mail: info@phoenixpeptide.com www.phoenixpeptide.com INTENDED
More informationSERIOUS ADVERSE EVENTS
EVENTS Introduction Timely reporting of Serious Adverse Events (SAEs) is required by regulations of the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). Such reporting is not
More informationHospital Systems. Systems. Research & Development
Hospital Systems H@H Systems Research & Development Item Oxygen has been working in the medical sector for almost 20 years, and have established ourselves as a requested and reliable name for technical
More informationMicrosphere Brachytherapy Sources and Devices
Microsphere Brachytherapy Sources and Devices REVISED AUGUST 2008 Questions should be directed to: Ashley Tull (240) 888-7129 or Ronald Zelac (301) 415-7635 or MedicalQuestions.Resource@nrc.gov Licensing
More informationAssessment of Health-Cost Externalities of Air Pollution in Denmark and Europe using the EVA Model System
Aarhus University Department of Environmental Science Assessment of Health-Cost Externalities of Air Pollution in Denmark and Europe using the EVA Model System J. Brandt 1, J. D. Silver 1, J. H. Christensen
More informationMay 26, Re: IVIG Administration Codes, RAC Audits
May 26, 2011 Re: IVIG Administration Codes, RAC Audits Arnold Balanoff, MD Chief Medical Officer Office of the Regional Administrator 601 E. 12th Street, Suite 235 Kansas City, MO 64106 In order to provide
More informationGenetic mechanisms of susceptibility to RSV disease
The Interplay Between Environmental Exposures and Infectious Agents: Session III Genetic mechanisms of susceptibility to RSV disease Steven R. Kleeberger Immunity, Inflammation, and Disease Laboratory
More informationHealth Effects Associated with Stack Chemical Emissions from NYS Natural Gas Compressor Stations:
Health Effects Associated with Stack Chemical Emissions from NYS Natural Gas Compressor Stations: 2008-2014 A Technical Report Prepared for the Southwest Pennsylvania Environmental Health Project D.O.
More informationIntegrating Genomics in Family Medicine
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Integrating Genomics in Family Medicine Brian Stello MD Lehigh Valley Health Network, Brian.Stello@lvhn.org Follow this and
More informationEmployer Training Manual
Employer Training Manual Table of Contents Introduction... 3 System Requirements... 3 Log On to CoreLink II... 3 Quick Start Menu... 4 Search & Patient (Employee) Information... 4 Search, View & Print
More informationPhase 1 SMA Type 2 Trial Initiation and Study Design. December 2017
Phase 1 SMA Type 2 Trial Initiation and Study Design December 2017 Disclaimers This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical
More informationMEDICAL LEAVE OF ABSENCE REQUEST FORM
MEDICAL LEAVE OF ABSENCE REQUEST FORM Section 1: For completion by the Employee The FMLA permits an employer to require that you submit a timely, complete, and sufficient medical certification to support
More informationMARRAKECH 2016 COP22 CMP12 CMA1 U N C L I M A T E C H A N G E C O N F E R E N C E
MARRAKECH 2016 COP22 CMP12 CMA1 U N C L I M A T E C H A N G E C O N F E R E N C E Session: Climate Change Friendly Economics and Sustainable Development. November 16, 2016 at 13:00 14:30 Pavilion Indonesia
More informationPACT. PACT Program. Production Assistance for Cellular Therapies
PACT Production Assistance for Cellular Therapies University of Wisconsin PACT-sponsored Workshop Developing Cellular Therapies: From Preclinical Safety To Clinical Evaluation Tuesday, April 09, 2013 Robert
More information4 th Annual Section of Labor and Employment Law Conference Chicago, IL November 3-6, 2010
4 th Annual Section of Labor and Employment Law Conference Chicago, IL November 3-6, 2010 FMLA Substantive Rights: Entitlements and Limitations Catherine J. Trafton Associate General Counsel International
More informationWhen an employee requests a PFL, the Leave Administrator will determine whether the
1 Hello and welcome to this overview of the new Paid Family Leave benefit for Syracuse University staff that will be available starting January 1, 2018. This overview is intended for managers and supervisors
More informationHuman IgG Rubella ELISA Kit
Human IgG Rubella ELISA Kit Catalog No: IRAPKT2020 Lot No: SAMPLE INTENDED USE The Rubella IgG ELISA is intended for use in evaluating a patient s serologic status to the rubella virus infection. It is
More informationLabGuide 13 How to Verify Performance Specifications
1 LG 13 Comments? Feedback? Questions? Email us at info@cola.org or call us at 800 981-9883 LabGuide 13 How to Verify Performance Specifications The verification of performance specifications confirms
More informationTRAINEE WORKBOOK A workshop for developing a Hazard Analysis Critical Control Points plan for your human milk bank
TRAINEE WORKBOOK A workshop for developing a Hazard Analysis Critical Control Points plan for your human milk bank haccp workshop: training workbook COPYRIGHT PATH Contact: Kiersten Israel Ballard, DrPH
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products. Proposed guidelines
0 0 0 0 WHO/PAC for BTPs_DRAFT/ Oct 0 ENGLISH ONLY Guidelines on procedures and data requirements for changes to approved biotherapeutic products Proposed guidelines NOTE: This document has been prepared
More informationUpdate from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products
Update from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products Peter Marks, M.D., Ph.D. FDLI 2017 Outline Products regulated Significance of
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationWhy Weight? Reducing the Influence of TV on Children s Health
FCD05-01 January 2005 Why Weight? Reducing the Influence of TV on Children s Health Teacher Guide Lesson Objectives: Participants will become aware of: the link between television viewing and childhood
More informationEvolving Evidence for Safe Oxygen Saturation Tradeoffs at the Tips and Tails
Evolving Evidence for Safe Oxygen Saturation Tradeoffs at the Tips and Tails Barbara K. Schmidt MD, FRCP, MSc Professor of Pediatrics Kristine Sandberg Knisely Chair in Neonatology Senior Scholar, Center
More information